CN101678068B - 不抑制n型钙通道而治疗中风和其他疾病 - Google Patents

不抑制n型钙通道而治疗中风和其他疾病 Download PDF

Info

Publication number
CN101678068B
CN101678068B CN200880014311.6A CN200880014311A CN101678068B CN 101678068 B CN101678068 B CN 101678068B CN 200880014311 A CN200880014311 A CN 200880014311A CN 101678068 B CN101678068 B CN 101678068B
Authority
CN
China
Prior art keywords
peptide
seq
tat
chimeric
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880014311.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101678068A (zh
Inventor
M·P·贝尔马里斯
J·D·加曼
P·S·卢
M·W·萨尔特
M·蒂米安斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Arbor Vita Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc, Arbor Vita Corp filed Critical NoNO Inc
Publication of CN101678068A publication Critical patent/CN101678068A/zh
Application granted granted Critical
Publication of CN101678068B publication Critical patent/CN101678068B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
CN200880014311.6A 2007-03-02 2008-02-29 不抑制n型钙通道而治疗中风和其他疾病 Expired - Fee Related CN101678068B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90450707P 2007-03-02 2007-03-02
US60/904,507 2007-03-02
PCT/US2008/002754 WO2008109010A1 (en) 2007-03-02 2008-02-29 Treating stroke and other diseases without inhibiting n-type calcium channels

Publications (2)

Publication Number Publication Date
CN101678068A CN101678068A (zh) 2010-03-24
CN101678068B true CN101678068B (zh) 2015-05-13

Family

ID=39738586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014311.6A Expired - Fee Related CN101678068B (zh) 2007-03-02 2008-02-29 不抑制n型钙通道而治疗中风和其他疾病

Country Status (9)

Country Link
US (2) US8288345B2 (enExample)
EP (1) EP2120987B1 (enExample)
JP (1) JP5631595B2 (enExample)
CN (1) CN101678068B (enExample)
AU (1) AU2008223469B2 (enExample)
CA (1) CA2679831C (enExample)
DK (1) DK2120987T3 (enExample)
ES (1) ES2446292T3 (enExample)
WO (1) WO2008109010A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
CA2657665C (en) * 2006-07-11 2015-06-02 Arbor Vita Corporation Method and compositions for treating stroke with fever
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
JP5801197B2 (ja) 2008-09-03 2015-10-28 ノノ インコーポレイテッド 痛みの治療に関する薬剤及び方法
CA2765169C (en) 2009-06-10 2019-06-18 Nono Inc. Model systems and treatment regimes for treatment of neurological disease
PT2440231T (pt) * 2009-06-10 2020-01-08 Nono Inc Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos
US9629892B2 (en) * 2010-08-12 2017-04-25 Nono Inc. Treatment of penetrative injury to the brain
WO2012050921A2 (en) * 2010-09-28 2012-04-19 Nono, Inc. Nd2 peptides and methods of treating neurological disease
HRP20220519T1 (hr) 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
EP2581384A1 (en) * 2011-10-11 2013-04-17 Institut Pasteur Products useful for the treatment of malignant neoplasms of the human nervous system
AU2012354072B2 (en) * 2011-12-13 2017-04-27 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
UA123820C2 (uk) 2014-05-28 2021-06-09 Ноно Інк. Хлоридна сіль пептиду tat-nr2b9c
CN104497106B (zh) * 2014-12-05 2017-05-10 华中科技大学 一种小分子多肽、其应用及产品
CN110049994B (zh) * 2016-12-08 2023-05-02 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
CN109232745B (zh) * 2018-09-18 2020-02-28 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽
AU2021206472A1 (en) * 2020-01-09 2022-08-18 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
EP4274596A4 (en) 2021-01-08 2024-12-25 NoNO Inc. Plasmin-resistant peptides for improved therapeutic index
CN113735939A (zh) * 2021-07-30 2021-12-03 英纳氏(珠海)药业有限公司 一种组合多肽及其应用
WO2026012336A1 (zh) * 2024-07-08 2026-01-15 福建盛迪医药有限公司 一种psd-95多肽抑制剂的可药用盐及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076561A2 (en) * 2002-03-09 2003-09-18 Artemis Pharmaceuticals Gmbh Recombinase fusion protein with enhanced cellular uptake

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6582698A (en) * 1997-03-19 1998-10-12 Johns Hopkins University, The Therapeutic uses of grip and grip-related molecules
WO2000001720A2 (en) * 1998-07-02 2000-01-13 President And Fellows Of Harvard College Compositions and methods for treating papillomavirus-infected cells
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
AU3368301A (en) * 2000-01-07 2001-07-16 Artemis Pharmaceuticals Gmbh Transduction of recombinases for inducible gene targeting
JPWO2005035562A1 (ja) * 2003-10-07 2007-11-22 伸弥 山中 新規な細胞増殖促進剤
WO2006084179A2 (en) * 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics Inc. Hiv tat-cd4 hybried molecules and methods of use thereof
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076561A2 (en) * 2002-03-09 2003-09-18 Artemis Pharmaceuticals Gmbh Recombinase fusion protein with enhanced cellular uptake

Also Published As

Publication number Publication date
WO2008109010A1 (en) 2008-09-12
EP2120987A4 (en) 2010-08-18
CA2679831A1 (en) 2008-09-12
US8288345B2 (en) 2012-10-16
CA2679831C (en) 2018-10-02
AU2008223469B2 (en) 2013-09-05
ES2446292T3 (es) 2014-03-07
EP2120987A1 (en) 2009-11-25
US20130172230A1 (en) 2013-07-04
AU2008223469A1 (en) 2008-09-12
CN101678068A (zh) 2010-03-24
JP2010520209A (ja) 2010-06-10
EP2120987B1 (en) 2014-01-15
US9061070B2 (en) 2015-06-23
JP5631595B2 (ja) 2014-11-26
DK2120987T3 (en) 2014-02-24
US20080274977A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
US9061070B2 (en) Treating stroke and other diseases without inhibiting N-type calcium channels
JP5801197B2 (ja) 痛みの治療に関する薬剤及び方法
US8080518B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US10046060B2 (en) Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NUONUO CORP.

Free format text: FORMER OWNER: ARBOR VITA CORP;NONO INC.

Effective date: 20130325

Free format text: FORMER OWNER: NUONUO CORP.

Effective date: 20130325

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130325

Address after: Ontario

Applicant after: NoNO Inc.

Address before: California, USA

Applicant before: Arbor Vita Corp.

Applicant before: NoNo Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150513